CBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Crescent Biopharma Inc (CBIO) is not a strong buy for a beginner, long-term investor at this time. While the company has promising analyst ratings and a robust oncology pipeline, its financial performance is weak, with no revenue and significant losses. Additionally, there are no immediate catalysts or trading signals to suggest a compelling entry point. A hold strategy is recommended until further clinical data or financial improvements emerge.
The MACD is positive at 0.424, indicating a potential upward trend, but it is contracting. RSI is at 73.755, which is neutral. Moving averages are converging, showing no clear trend. Key resistance levels are R1: 12.886 and R2: 14.006, while support levels are S1: 9.261 and S2: 8.141. Overall, the technical indicators suggest no strong buy signal.
Analysts have initiated coverage with 'Overweight' and 'Buy' ratings, with a $35 price target, indicating significant upside potential.
The company has partnered with Sichuan Kelun-Biotech and launched the ASCEND global clinical trial for its lead asset CR-
A $185 million private placement ensures operational funding through 2028.
No revenue generation and significant net losses (-$24.6 million in Q3 2025).
EPS dropped significantly (-90.22% YoY).
No immediate clinical data readouts until Q1 2027, delaying potential value realization.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of $24.6 million, though net income improved by 150.47% YoY. EPS dropped sharply by -90.22% YoY to -1.49. Gross margin remains at 0%.
Analysts from Piper Sandler and Guggenheim initiated coverage with 'Overweight' and 'Buy' ratings, respectively, and a $35 price target. They are optimistic about the company's oncology pipeline, particularly CR-001 and its ADCs, with potential for significant revenue by 2036.
